NDC 70860-225
Bortezomib
Bortezomib
Bortezomib is a Intravenous; Subcutaneous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Athenex Pharmaceutical Division, Llc.. The primary component is Bortezomib.
| Product ID | 70860-225_49aeb918-1016-4748-aa7a-53c51014e650 |
| NDC | 70860-225 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Bortezomib |
| Generic Name | Bortezomib |
| Dosage Form | Injection, Powder, Lyophilized, For Solution |
| Route of Administration | INTRAVENOUS; SUBCUTANEOUS |
| Marketing Start Date | 2022-05-06 |
| Marketing Category | ANDA / |
| Application Number | ANDA210824 |
| Labeler Name | Athenex Pharmaceutical Division, LLC. |
| Substance Name | BORTEZOMIB |
| Active Ingredient Strength | 4 mg/1 |
| Pharm Classes | Proteasome Inhibitor [EPC], Proteasome Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |